共 50 条
- [21] Biomarkers, Cardiovascular Outcomes and Effect of Ezetimibe After Acute Coronary Syndrome in the IMPROVE-IT TrialCIRCULATION, 2017, 136Qamar, ArmanGiugliano, Robert P.Blazing, Michael A.Park, Jeong G.Murphy, Sabina A.Cannon, Christopher P.Braunwald, EugeneMorrow, David A.
- [22] Comparison of Adverse Outcomes After Contemporary Percutaneous Coronary Intervention in Women Versus Men With Acute Coronary SyndromeAMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (08): : 1092 - 1098Pendyala, Lakshmana K.Torguson, RebeccaLoh, Joshua P.Kitabata, HironoriMinha, Sa'arBadr, SalemDvir, DannyBarbash, Israel M.Satler, Lowell F.Pichard, Augusto D.Waksman, Ron
- [23] Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary RevascularizationJOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (01):Udell, Jacob A.Koh, MariaQiu, FengAustin, Peter C.Wijeysundera, Harindra C.Bagai, AkshayYan, Andrew T.Goodman, Shaun G.Tu, Jack V.Ko, Dennis T.
- [24] APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIALJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 75 - 75Hagstrom, EmilSteg, Philippe GabrielSzarek, MichaelBhatt, DeepakBittner, VeraDanchin, NicolasDiaz, RafaelGoodman, ShaunHarrington, Robert A.Jukema, Johan WouterKim, Yong-UnLiberopoulos, EvangelosMarx, NikolausMcGinniss, JenniferRoe, MatthewLouie, MichaelWhite, HarveyZeiher, AndreasSchwartz, Gregory G.
- [25] CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIALJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)Bansal, ShantiWackers, Frans J. Th.Inzucchi, SilvioYoung, Lawrence H.Chyun, Deborah A.
- [26] Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trialEUROPEAN HEART JOURNAL, 2020, 41 : 1736 - 1736Schwartz, G. G.Szarek, M.Bhatt, D. L.Bittner, V. A.Diaz, R.Goodman, S. G.Harrington, R. A.Jukema, J. W.Kim, Y. U.Li, Q. H.Manvelian, G.White, H. D.Zeiher, A. M.Steg, P. G.
- [27] Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trialJOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 741 - 747Toth, Peter P.Jones, Steven R.Slee, AprilFleg, JeromeMarcovina, Santica M.Lacy, MeganMcBride, RuthBoden, William E.
- [28] Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMESEUROPEAN HEART JOURNAL, 2019, 40 : 682 - 682Schwartz, G.Szarek, M.Li, Q. H.Chiang, C. E.Diaz, R.Hagstrom, E.Huo, Y.Jukema, J. W.Lecorps, G.Moryusef, A.Pordy, R.White, H. D.Yusoff, K.Zeiher, A. M.Steg, P. G.
- [29] Effect of Alirocumab in Patients With Recent Acute Coronary Syndrome According to Renal Function: A Prespecified Analysis of the ODYSSEY OUTCOMES TrialCIRCULATION, 2019, 140Tunon, JoseSteg, Philippe G.Bhatt, Deepak L.Bittner, Vera A.Diaz, RafaelGoodman, Shaun G.Jukema, J. WouterKim, Yong-UnLi, Qian H.Mueller, ChristianParkhomenko, AlexanderPordy, RobertSritara, PiyamitrSzarek, MichaelWhite, Harvey D.Zeiher, Andreas M.Schwartz, Gregory G.
- [30] Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialDIABETES CARE, 2025, 48 (04)Schwartz, Gregory G.Szarek, MichaelJukema, J. WouterCobbaert, Christa M.Reijnders, EstherBittner, Vera A.Schwertfeger, MarkusBhatt, Deepak L.Fazio, SergioGaron, GenevieveGoodman, Shaun G.Harrington, Robert A.White, Harvey D.Steg, Philippe Gabriel